Immunosuppressive therapy of rheumatoid arthritis (RA) with the thiopurine azathioprine (IMURAN (R)) has been reported since 1965. The initial experiences with this drug stimulated some enthusiasm and there were 11 publications in the period 1965-1970.5 22 45 51 72 129 143 150 206 207 212 In the next five years (1971) (1972) (1973) (1974) (1975) , the problems of significant haematological toxicity and the possibility of malignancy in renal transplantation patients treated with azathioprine caused concern, so that less investigation and interest was evident during these years. Major studies were reported again in [1976] [1977] and some of these, especially those by Balken,12 Berry et al, 18 Dwosh et al5" and Goebel et al,8°stimulated re-evaluation of the place of azathioprine in the treatment of rheumatoid arthritis. A total of 24 studies published in the English literature, or available in translation, over an 11-year period is now available for review to assess the composite adverse experience with azathioprine in this non-transplant disease category.
Methods of review
A composite azathioprine literature listing, including computerised reference banks, was first used to establish a primary literature data base. There are, as always, multiple citations which mention azathioprine for RA but which give no clinical data or patient tabulated from the literature. The occurrence of multiple blood count abnormalities in one patient was confirmed in these reviews. The study by Levyetal, 523 in which a higher mean dose of azathioprine (2 9 mg/kg/day) was used, included a relatively high incidence of leucopenia. A patient's disease activity measurements did not correlate with the degree of leucopenia.
Gastrointestinal complaints were reported 103 times in the 542 patients, an incidence of 19 % (fig 2) . Approximately 10% of patients had nausea and /or vomiting, and gastrointestinal symptoms, not otherwise specified, were reported in 6 % of patients. Other symptomatology was reported in less than 1 % of the total for each of the following: anorexia six cases, ulceration four cases, diarrhoea two cases and ulcer two cases. Two gastrointestinal toxicities, reported in other investigational uses of azathioprine, were not found in a significant percentage in this review. There were only two reports of hepatotoxicity, a significant problem in the use of azathioprine in renal transplantation. There was only one report of idiosyncratic, or 'allergic', pancreatitis which has been reported in inflammatory bowel disease treated with azathioprine.
The review paid particular attention to patient withdrawal and to prohibitive or life-threatening reactions reported by the authors. Interruption of azathioprine treatment, or withdrawal of patients, was mentioned in relation to both haematological and gastrointestinal toxicity. Eighty-one patients were withdrawn because of drug-related adverse reactions (15%).
Reports of infection (24%) in the context of this immunosuppressive therapy were lower than might have been expected, with most of these being bacterial infection of a non-threatening nature. Five patients, in three reports published before 1970, died 
